Trial of Gemcitabine With or Without MSC1936369B in Pancreatic Cancer
Status:
Completed
Trial end date:
2015-04-30
Target enrollment:
Participant gender:
Summary
The research trial is testing the experimental treatment MSC1936369B in combination with
Gemcitabine, in subjects with metastatic pancreatic adenocarcinoma. The study will be run in
two parts:
Safety Run-In: Will determine the Maximum Tolerated Dose (MTD) and the recommended Phase II
dose of MSC1936369B, when combined with gemcitabine, in subjects with metastatic pancreatic
adenocarcinoma.
Phase II: Will assess the anti-tumor activity of MSC1936369B combined with gemcitabine
compared to gemcitabine alone as first line treatment in subjects with metastatic pancreatic
adenocarcinoma.